Screener
Gilead Sciences GILD AOCI
AOCI at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
FAQ
- What is Gilead Sciences's AOCI?
- Gilead Sciences (GILD) reported AOCI of $95M in Q2 2026.
- How has Gilead Sciences's AOCI changed year-over-year?
- Gilead Sciences's AOCI increased by 627.8% year-over-year, from -$18M to $95M.
- What is the long-term trend for Gilead Sciences's AOCI?
- Over 5 years (2020 to 2025), Gilead Sciences's AOCI has grown at a -8.3% compound annual growth rate (CAGR), from -$60M to $39M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Gilead Sciences's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude